AJCN Yamada Bee Farm Grant for Honeybee Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trumbo, P. R
Right arrow Articles by Ellwood, K. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trumbo, P. R
Right arrow Articles by Ellwood, K. C
Agricola
Right arrow Articles by Trumbo, P. R
Right arrow Articles by Ellwood, K. C
American Journal of Clinical Nutrition, Vol. 84, No. 5, 971-974, November 2006
© 2006 American Society for Nutrition


SPECIAL ARTICLE

Lutein and zeaxanthin intakes and risk of age-related macular degeneration and cataracts: an evaluation using the Food and Drug Administration's evidence-based review system for health claims1,2,3

Paula R Trumbo and Kathleen C Ellwood

1 From the Division of Nutrition Programs and Labeling, Food and Drug Administration, College Park, MD

The labeling of health claims that meet the significant scientific agreement standard and of qualified health claims on conventional foods and dietary supplements requires premarket approval by the Food and Drug Administration (FDA). The FDA conducts an evidence-based review to ascertain whether sufficient evidence exists to support a significant scientific agreement standard or a qualified health claim. The FDA recently reviewed intervention and observational studies that evaluated the role of lutein and zeaxanthin in reducing the risk of age-related macular degeneration and cataracts. On the basis of this evidence-based review, the FDA concluded that no credible evidence exists for a health claim about the intake of lutein or zeaxanthin (or both) and the risk of age-related macular degeneration or cataracts.

Key Words: Lutein • zeaxanthin • age-related macular degeneration • cataracts • health claims




This article has been cited by other articles:


Home page
cfpHome page
A. Zhou, N. Weizblit, and J. Noble
Answer: Answer to Ophthaproblem
Can Fam Physician, December 1, 2008; 54(12): 1700 - 1700.
[Full Text] [PDF]


Home page
J. Nutr.Home page
A. H. Lichtenstein, E. A. Yetley, and J. Lau
Application of Systematic Review Methodology to the Field of Nutrition
J. Nutr., December 1, 2008; 138(12): 2297 - 2306.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M. Dherani, G. V. S. Murthy, S. K. Gupta, I. S. Young, G. Maraini, M. Camparini, G. M. Price, N. John, U. Chakravarthy, and A. E. Fletcher
Blood Levels of Vitamin C, Carotenoids and Retinol Are Inversely Associated with Cataract in a North Indian Population
Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3328 - 3335.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
L. Zhao and B. V. Sweet
Lutein and zeaxanthin for macular degeneration
Am. J. Health Syst. Pharm., July 1, 2008; 65(13): 1232 - 1238.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The American Society for Nutrition